Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment
作者： R Champlin , J Gajewski , S Nimer , S Vollset , E Landaw
DOI: 10.1200/JCO.1990.8.7.1199
关键词:
摘要: Results of postremission chemotherapy for adults with acute myelogenous leukemia (AML) were assessed in two sequential prospective studies involving similar induction therapy and courses intensive consolidation treatment. Fifty-six patients achieving remission on the protocol (ALP3) study received high-dose cytarabine daunorubicin as course one standard-dose two. are compared forty-six ALP2 who azacitidine doxorubicin cytarabine, daunorubicin, thioguanine The ALP3 regimen resulted a significantly improved 5-year disease-free survival 32% +/- 19% versus 20% 11% (P = .03). Survival from was also improved, 40% 14% 24% 12% less than .01). Favorable prognostic factors included receiving treatment regimen, absence prio...
sci-hub.se 参考文章(26)
JM Hows, JL Yin, J Marsh, D Swirsky, L Jones, JF Apperley, DC James, S Smithers, JR Batchelor, JM Goldman, Histocompatible Unrelated Volunteer Donors Compared With HLA Nonidentical Family Donors in Marrow Transplantation for Aplastic Anemia and Leukemia Blood. ,vol. 68, pp. 1322- 1328 ,(1986) , 10.1182/BLOOD.V68.6.1322.1322
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
W. P. Dixon, BMPD statistical software manual Berkeley: University of California Press. ,(1988)
S B Kahn, C B Begg, J J Mazza, J M Bennett, H Bonner, J H Glick, Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. Journal of Clinical Oncology. ,vol. 2, pp. 865- 870 ,(1984) , 10.1200/JCO.1984.2.8.865
M S Tallman, F R Appelbaum, D Amos, R S Goldberg, R B Livingston, J Mortimer, P L Weiden, E D Thomas, Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. Journal of Clinical Oncology. ,vol. 5, pp. 918- 926 ,(1987) , 10.1200/JCO.1987.5.6.918
R H Herzig, H M Lazarus, S N Wolff, G L Phillips, G P Herzig, High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. Journal of Clinical Oncology. ,vol. 3, pp. 992- 997 ,(1985) , 10.1200/JCO.1985.3.7.992
R H Herzig, J D Hines, G P Herzig, S N Wolff, P A Cassileth, H M Lazarus, D J Adelstein, R A Brown, P F Coccia, S Strandjord, Cerebellar toxicity with high-dose cytosine arabinoside. Journal of Clinical Oncology. ,vol. 5, pp. 927- 932 ,(1987) , 10.1200/JCO.1987.5.6.927
H D Preisler, A Raza, A Early, J Kirshner, M Brecher, A Freeman, Y Rustum, N Azarnia, R Priore, A Sandberg, Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. Journal of Clinical Oncology. ,vol. 5, pp. 722- 730 ,(1987) , 10.1200/JCO.1987.5.5.722
J D Hines, M M Oken, J J Mazza, A M Keller, R R Streeter, J H Glick, High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. Journal of Clinical Oncology. ,vol. 2, pp. 545- 549 ,(1984) , 10.1200/JCO.1984.2.6.545
V Heinemann, E Estey, M J Keating, W Plunkett, Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. Journal of Clinical Oncology. ,vol. 7, pp. 622- 628 ,(1989) , 10.1200/JCO.1989.7.5.622